|Bid||14.50 x 800|
|Ask||18.00 x 800|
|Day's Range||16.00 - 17.75|
|52 Week Range||16.00 - 30.89|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.67|
UROGEN PHARMA (URGN) delivered earnings and revenue surprises of 7.14% and -10.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the first quarter ended March 31, 2021 and provided an overview of the Company’s recent developments.
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / UroGen Pharma Ltd. (NASDAQ:URGN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 8:30 AM Eastern Time.